Coloplast Holds 6% Organic Growth as US Reimbursement Bites

Coloplast AS (OTC: CLPBF) reported 6% organic revenue growth and 5% EBIT growth in constant currencies for its fiscal third quarter of 2026, while flagging US reimbursement headwinds and inventory adjustments in China; the US-quoted shares last closed at 65.22, up 0.32%.

Coloplast AS (OTC: CLPBF), the Danish maker of ostomy, continence, wound and skin care products, told investors on its fiscal third-quarter 2026 earnings call that organic revenue grew 6% and earnings before interest and tax rose 5% in constant currencies. The headline is a steady one. What sits underneath it is less comfortable: reimbursement pressure in the United States and inventory adjustments in China, two of the most consequential markets in medtech, pulling in the opposite direction from the growth engine.

The US-quoted shares last changed hands at 65.22, up 0.32% from the prior close of 65.02, with the day’s range pinned at a single price — a reminder that this is a thinly traded American depositary line on a company whose primary listing and liquidity sit in Copenhagen. The muted reaction came on a session in which the broader American market slipped: the S&P 500 tracker closed at $767.45, down 0.68%, and the Nasdaq 100 tracker at $717.51, down 1.69%.

Organic growth is the number that matters here

“Organic” growth strips out the effect of currency translation and acquisitions or disposals, leaving the change in underlying volume and price. For a company with the geographic spread of Coloplast — Danish cost base, revenue collected in dollars, euros, renminbi and a long tail of emerging-market currencies — the gap between reported and organic figures can be wide enough to obscure what the business is actually doing.

That is why the 6% organic figure, reported by GuruFocus from the call, is the line management chose to lead with. It says the chronic-care franchise is still compounding at a mid-single-digit clip despite what the company described as US momentum coexisting with reimbursement friction.

EBIT growing slower than revenue is the tell

The more interesting relationship in the release is the one between the two growth rates. Revenue grew 6% organically; EBIT grew 5% in constant currencies. When operating profit expands more slowly than sales, operating margin is compressing, not expanding — the opposite of what a business with Coloplast’s pricing reputation would normally deliver at this stage of a cycle.

There are only a handful of explanations that fit, and the company named two of them itself. Reimbursement headwinds in the United States mean the price paid per unit by payers is under pressure, so revenue growth is being bought with volume rather than price. Volume growth at flat or falling realised prices carries the full cost of goods with it and dilutes margin. Inventory adjustments in China — distributors and hospitals working down stock rather than reordering — hit the highest-margin incremental sales first, because those are the ones that arrive without additional selling cost attached.

The company did not, on the basis of what was disclosed, quantify either drag as a separate line. Investors who want that arithmetic will have to wait for the full report and the segment detail.

US reimbursement is a sector-wide problem, not a Coloplast one

Coloplast sells consumables into a market where the customer is chronically ill, the product is used daily and the payer is usually a government programme or an insurer rather than the patient. That model produces enviable recurring revenue and it also concentrates risk in a single variable: what the payer agrees to pay per item.

Every manufacturer in ostomy and continence care is exposed to the same variable, and pressure on American reimbursement rates has been a running theme across the medical-device consumables complex. The strategic question for Coloplast is whether it can convert the volume it is winning in the US into margin once the reimbursement reset works through, or whether the American business permanently carries a lower profitability profile than the European core.

What the China drag does and does not signal

Inventory adjustments are a timing effect, not a demand verdict. When a distributor destocks, the sales the manufacturer loses in one quarter are, in principle, deferred rather than destroyed — assuming end-patient demand holds. The risk is that destocking in China is rarely purely commercial; volume-based procurement, tender pricing and hospital budget cycles all feed into it, and each of those can reset the price level rather than merely delay the order.

Investors should treat the China line as the item most likely to look different in a quarter’s time, in either direction.

What to watch in the next print

Three things will determine whether the 6% organic rate is a floor or a ceiling.

• The revenue-to-EBIT spread. If organic revenue growth and constant-currency EBIT growth converge, or EBIT overtakes revenue, the reimbursement and destocking effects are annualising out. If the gap widens, margin pressure is structural rather than transitional.
• Whether the US contribution is priced or volumed. Management framed the American business as a source of momentum. The follow-up question is whether that momentum survives contact with the reimbursement environment at an acceptable gross margin.
• China reordering. A return to normal ordering patterns would show up as an outsized organic contribution from Asia in a subsequent quarter. Continued destocking would suggest a reset in underlying demand or price.

How to read the share price reaction

A 0.32% move on the American line tells you almost nothing about how the market received the numbers. The volume in CLPBF is a fraction of the Copenhagen listing’s, the day’s range collapsed to a single print, and the quote reflects the Danish close translated into a US-traded instrument rather than active American price discovery. Anyone using CLPBF as a read on sentiment should treat it as a reference price, not a verdict — particularly against a session where the Nasdaq 100 tracker fell 1.69% and the Dow tracker closed at $532.91, down 0.24%.

The substance for shareholders is simpler than the tape. Coloplast is still growing sales at a mid-single-digit organic rate in a business built on recurring consumable demand from chronically ill patients, which is about as defensive a revenue base as medtech offers. It is also, for now, converting that growth into slightly less profit growth than the top line implies. Whichever of those two facts turns out to be the temporary one will set the direction of the stock over the next several quarters.

Key facts

• Organic revenue growth (Q3 2026): 6%
• EBIT growth, constant currencies: 5%
• CLPBF last close: 65.22, +0.32% (as of 18 Aug 2026, 20:00 GMT)
• Named headwinds: US reimbursement pressure; China inventory adjustments

Frequently asked questions

What did Coloplast report for fiscal Q3 2026?

Coloplast reported 6% organic revenue growth and 5% EBIT growth measured in constant currencies for its fiscal third quarter of 2026. On the earnings call, management also flagged two offsetting pressures: reimbursement headwinds in the United States and inventory adjustments among customers in China. Neither drag was separately quantified in the material disclosed.

Why does it matter that EBIT grew slower than revenue?

When operating profit grows 5% while organic revenue grows 6%, operating margin is compressing rather than expanding. That pattern is consistent with growth being driven by volume at flat or falling realised prices, which carries the full cost of goods, and with the loss of higher-margin incremental sales in a destocking market such as China.

What are US reimbursement headwinds?

Reimbursement is the amount a government programme or insurer pays for each medical product a patient uses. Coloplast sells daily-use consumables in ostomy and continence care, so its revenue per unit depends heavily on those payer-set rates. When rates are cut or tightened, the manufacturer must win more volume to hold revenue, which dilutes margin.

What does ‘organic growth’ exclude?

Organic growth strips out the effects of currency translation and of acquisitions or disposals, leaving only underlying change in volume and price. For a Danish company earning in dollars, euros and renminbi, reported growth can diverge sharply from organic growth, which is why management leads with the organic figure as the cleaner measure of trading performance.

How did CLPBF shares trade around the results?

CLPBF last changed hands at 65.22, up 0.32% from a prior close of 65.02, as of 18 August 2026 at 20:00 GMT. The day’s range showed a single price, reflecting very thin trading in the US-quoted line. Coloplast’s primary listing and genuine price discovery sit in Copenhagen, not the United States.

Is the China inventory issue a demand problem?

Inventory adjustments are primarily a timing effect: when distributors or hospitals run down stock instead of reordering, sales are deferred rather than lost, provided end-patient demand holds. The risk is that Chinese destocking often accompanies tender pricing and procurement changes, which can reset price levels rather than merely delay orders. The next quarter should clarify which applies.

Sources

• Coloplast AS (CLPBF) (Q3 2026) Earnings Call Highlights: Organic Growth Steady at 6% Amid US … — GuruFocus

Photo: EqualStock IN · Pexels Licence — source